Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIYABRO: CBM588 with platinum-based chemotherapy + pemetrexed + pembrolizumab in NSCLC
jRCT1071260004Recruiting
- Start
- Apr 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of clostridium butyricum in Non-small cell lung cancer (NS-NSCLC). Primary endpoints: Progression-free survival and Response rate. Started Apr 2026; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT1071260004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071260004.